Research Analysts Offer Predictions for MIRM FY2024 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Leerink Partnrs upped their FY2024 earnings estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($1.60) per share for the year, up from their prior estimate of ($1.63). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q4 2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.83) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.57) EPS.

Several other brokerages have also recently commented on MIRM. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Citigroup boosted their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners boosted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $57.10.

Mirum Pharmaceuticals Trading Up 4.1 %

MIRM stock opened at $48.65 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $49.27. The business has a 50-day simple moving average of $43.65 and a 200 day simple moving average of $41.40.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the sale, the chief executive officer now owns 119,359 shares of the company’s stock, valued at $5,110,952.38. The trade was a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jolanda Howe sold 2,500 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the transaction, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at approximately $114,264.60. This represents a 50.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 19,706 shares of company stock worth $875,697. 22.87% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after acquiring an additional 1,003 shares during the period. R Squared Ltd bought a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $69,000. Secure Asset Management LLC lifted its position in shares of Mirum Pharmaceuticals by 9.3% in the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock worth $1,651,000 after purchasing an additional 3,406 shares during the period. Avanza Fonder AB bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $189,000. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Mirum Pharmaceuticals by 25.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after purchasing an additional 29,545 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.